Butts Arielle, Palmer Glen E, Rogers P David
a Department of Clinical Pharmacy , University of Tennessee Health Science Center , Memphis , TN , USA.
Virulence. 2017 Feb 17;8(2):198-210. doi: 10.1080/21505594.2016.1216283. Epub 2016 Jul 26.
As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.
随着系统性真菌感染的发生率持续上升，抗真菌药物耐药性愈发普遍，迫切需要新的治疗选择。系统性抗真菌药物种类有限，这一问题进一步恶化。然而，新型抗真菌药物的发现、开发和批准是一个漫长的过程，通常需要数十年。因此，将现有疗法与各种佐剂联合使用的可能性引发了越来越多的关注和研究，这些佐剂要么增强活性，要么克服现有的耐药机制。抗真菌佐剂的报道范围从植物提取物到重新利用的化合物，再到合成肽。这种方法可能会延长目前已批准的抗真菌药物的效用，并减轻耐药性的持续发展。
